Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Update

Aadi Bioscience, Inc. (NASDAQ:AADI) was the target of a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 706,400 shares, an increase of 49.4% from the January 15th total of 472,700 shares. Approximately 3.5% of the company’s shares are short sold. Based on an average daily trading volume, of 357,800 shares, the short-interest ratio is currently 2.0 days.

Institutional Trading of Aadi Bioscience

A number of institutional investors and hedge funds have recently modified their holdings of AADI. BML Capital Management LLC grew its position in shares of Aadi Bioscience by 5.0% during the fourth quarter. BML Capital Management LLC now owns 2,100,000 shares of the company’s stock worth $6,626,000 after acquiring an additional 100,000 shares during the last quarter. Peapod Lane Capital LLC bought a new position in Aadi Bioscience in the 4th quarter valued at about $1,397,000. Geode Capital Management LLC grew its position in Aadi Bioscience by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 217,294 shares of the company’s stock valued at $686,000 after buying an additional 8,546 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Aadi Bioscience in the 3rd quarter valued at about $32,000. 52.08% of the stock is owned by institutional investors and hedge funds.

Aadi Bioscience Price Performance

AADI opened at $2.68 on Thursday. The stock has a market capitalization of $66.20 million, a PE ratio of -1.18 and a beta of 0.64. The firm’s fifty day moving average price is $2.90 and its 200 day moving average price is $2.25. Aadi Bioscience has a 12-month low of $1.21 and a 12-month high of $3.81.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.